Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant hypofractionated radiotherapy plus sintilimab after hepatectomy for high-risk BCLC A hepatocellular carcinoma
ChiCTR2300075299Phase 2Recruiting
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Eastern Hepatobiliary Surgery Hospital. Primary endpoint: Recurrence-free survival. Started Jun 2023; status: recruiting.
02
Drugs
sintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300075299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075299.